FRAMINGHAM, Mass.--(BUSINESS WIRE)--ATryn® (Antithrombin [Recombinant]) is now available commercially through Lundbeck Inc. of Deerfield, IL, a wholly owned subsidiary of H. Lundbeck A/S in Denmark (LUN: Copenhagen Stock Exchange), GTC Biotherapeutics, Inc.’s (“GTC”, NASDAQ: GTCB) commercialization and development partner in the United States. GTC is due to receive a total of $1 million from Lundbeck for its initial inventory of ATryn.
